| Literature DB >> 32633563 |
Tomas Pascual1,2, Juan M Cejalvo3,4, Mafalda Oliveira1,5,6, Maria Vidal1,2,7,8, Estela Vega9, Sergi Ganau10, Ana Julve11, Esther Zamora5,6, Ignacio Miranda12, Ana Delgado13, Begoña Bermejo3,4, Luis de la Cruz-Merino14,15, Manel Juan1,7,16,17, Juan M Ferrero-Cafiero1, Jordi Canes1, Xavier Gonzalez1,18, Patricia Villagrasa1, Aleix Prat1,2,7,8.
Abstract
New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti-PD-1/PD-L1 or anti-CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent. The presence of residual cancer after neoadjuvant chemotherapy in early breast cancer patients is an unmet medical need. SOLTI-1503 PROMETEO is a window of opportunity trial, which evaluates the combination of talimogene laherparepvec in combination with atezolizumab in women with operable HER2-negative breast cancer who present residual disease after neoadjuvant chemotherapy. The primary end point is the rate of residual cancer burden 0/1. Clinical Trial Registration: NCT03802604.Entities:
Keywords: PD-L1; atezolizumab; immunotherapy; luminal B breast cancer; residual disease; talimogene laherparepvec; triple-negative breast cancer
Mesh：
Substances：
Year: 2020 PMID： 32633563 DOI： 10.2217/fon-2020-0246
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404